Gene Therapy for Sickle Cell Disease

Area of Science:

• Hematology
• Genetics
• Medical Science

Background:

• Sickle cell disease (SCD) is a genetic blood disorder characterized by abnormal red blood cells, leading to severe complications like vaso-occlusion and organ damage.
• Genetic approaches are emerging as a curative treatment strategy for SCD.
• Understanding SCD pathophysiology is crucial for developing effective gene therapies.

Purpose of the Study:

• To review the current landscape of gene therapy for SCD.
• To present an institution's experience and outcomes with SCD gene therapy.
• To inform readers about the advancements and clinical application of gene therapy in SCD management.

Main Methods:

• Gene therapy involves using a patient's own stem cells, genetically modified to correct the SCD-causing mutation.
• Two primary approaches include gene addition/transfer and gene editing.
• Treatment is a complex, multi-step process requiring interdisciplinary collaboration and ongoing clinical trials.

Main Results:

• Two gene therapy products for SCD received FDA approval in 2023.
• At one center, 17 patients completed gene therapy trials with no serious adverse events.
• All treated patients remain alive and stable, indicating the safety and efficacy of the therapy.

Conclusions:

• Gene therapy is a developing and promising treatment option for SCD.
• Nurses are vital in educating patients and families about gene therapy.
• Close nursing coordination and supportive care are essential throughout the gene therapy process, including follow-up.